TP53 and small cell lung carcinoma: In light of this, a tumor vaccine consisting of autologous dendritic cells transduced with wild-type p53 gene delivered by an adenovirus (Ad.p53 DC) was developed and tested in a Phase I/II trial in patients with ES-SCLC who had progressed on prior chemotherapy (47).